Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.): Bendamustine Hydrochloride Injection, Solution to be discontinued
Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.): Bendamustine Hydrochloride Injection, Solution to be discontinued. Its amount of 1 is below the median of 3 (29th percentile). Dated 105 days ago, it serves as a historical benchmark. Score 60/100. As of 2026-11-04, from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list).
Data as of · Compiled by Zalwin from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)
amount: 1 · 29th percentile of 353 DrugShortagePulse records · 0.3x the median
Free preview: all 12 published fields of this record are shown below. Locked: 352 related DrugShortagePulse records and the 5-column CSV export.
| Field | Value |
|---|---|
| Manufacturer | Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.) |
| Drug | Bendamustine Hydrochloride Injection, Solution |
| Dosage form | Injection |
| Therapeutic category | Oncology |
| Status | To Be Discontinued |
| Stage | Manufacturer discontinuation |
| Presentations affected | 1 |
| Package NDCs | 63459-390-08 |
| Manufacturer supply note | A business decision has been made to discontinue manufacture of the drug. |
| Discontinued date | 2026-07-23 |
| First posted | 2026-07-23 |
| Updated | 2026-07-23 |
| amount percentile | 29th of 353 (median 3, 0.3x median) |
| Peer records CSV (353 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.) + all 353 records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Manufacturer · Drug · Stage · Availability · Updated · official source URL
- Source agency: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)
- Record date: 2026-07-23
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top DrugShortagePulse records: Sanofi-Aventis U.S. LLC · Fresenius Kabi USA, LLC · Hospira, Inc., a Pfizer Company · Fresenius Kabi USA, LLC · Hospira, Inc., a Pfizer Company · Browse all by state and category →
LIVE PUBLIC DATA Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) · Last refreshed: Wed, 04 Nov 2026 06:10:12 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
60 / 100 Score
- The manufacturer is leaving the market.
- Sterile injectable: hospital and 503B demand.
What is the DrugShortagePulse record for Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)?
Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)'s Bendamustine Hydrochloride Injection, Solution is on the FDA drug shortage list. Manufacturer discontinuation. Last updated 2026-07-23.
How does Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.) compare to other DrugShortagePulse records?
Its amount of 1 is below the median (29th percentile); smaller records often move faster and face less competition. It is 105 days old; check the official source for later updates before acting.
Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.) vs. top 3 peers
| Organization | Amount | Percentile | Record date |
|---|---|---|---|
| Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.) | 1 | 29th | 2026-07-23 |
| Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | 1 | 29th | 2026-10-14 |
| Fresenius Kabi USA, LLC | 1 | 29th | 2026-09-21 |
| Fresenius Kabi USA, LLC | 1 | 29th | 2026-09-16 |
Related records
- Baxter Healthcare
- Baxter Healthcare
- Baxter Healthcare
- Sanofi-Aventis U.S. LLC
- Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
- Fresenius Kabi USA, LLC
- Fresenius Kabi USA, LLC
- Par Health, USA LLC
- Hospira, Inc., a Pfizer Company
- Merck Sharp & Dohme LLC
- Eli Lilly and Co.
- Eli Lilly and Co.
DrugShortagePulse: Manufacturer discontinuation DrugShortagePulse: Oncology
How to monitor Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.) and peer oncology records
Get new DrugShortagePulse records like Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.) by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new shortages in your categories
DrugShortagePulse emails new and changed FDA drug shortages matching your therapeutic categories.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.